The clinical relevance of the overexpression of HER-2 in breast cancer;La relevancia clínica de la sobreexpresión de HER-2 en el cáncer de mama

Anales de Medicina Interna

Volumn 23, Issue 3, 2006, Pages 103-104

  Khosravi Shahi, P ^a   Perez Manga G ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

BREAST CANCER; EDITORIAL; PROTEIN EXPRESSION; BREAST TUMOR; CANCER INVASION; CLASSIFICATION; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROTO ONCOGENE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ERBB-2; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 33746811481     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. Raetz EA, Moos PJ. Impact of microarray technology in clinical oncology. Cancer Invest 2004; 22: 312-20.
2. 7. O'Connell P. Genetic and cytogenetic analyses of breast cancer yield different perspectives of a complex disease. Breast Cancer Res Treat 2003; 78: 347-9.
3. Burstein HJ. The distinctive nature of HER2 of breast cancers. N Engl J Med 353; 16: 1652-1654.
4. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
5. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-70.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
7. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med 2003; 348: 2339-47.
8. Bell R. What can we learn from Herceptin trials in metastatic breast cancer? Oncology 2002; 63: 39-46.
9. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 1215-21.
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.